The fda approves eylea hd the treatment of patients with macular edema following retinal vein occlusion. The fda evaluated libtayo under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions An additional regulatory application is also under review in the european union, with a decision expected by the first half of 2026. Full prescribing information for libtayo will be posted on drugs@fda. Second fda approval for tevimbra in 2024
OPEN
